Cargando…

European survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation

AIMS: Duty-cycled radiofrequency ablation (RFA) has been used for atrial fibrillation (AF) for around 5 years, but large-scale data are scarce. The purpose of this survey was to report the outcome of the technique. METHODS AND RESULTS: A survey was conducted among 20 centres from seven European coun...

Descripción completa

Detalles Bibliográficos
Autores principales: Scharf, C., Ng, G.A., Wieczorek, M., Deneke, T., Furniss, S.S., Murray, St., Debruyne, Ph., Hobson, N., Berntsen, R.F., Schneider, M.A., Hauer, H.A., Halimi, F., Boveda, S., Asbach, S., Boesche, L., Zimmermann, M., Brigadeau, F., Taieb, J., Merkel, M., Pfyffer, M., Brunner-La Rocca, H.P., Boersma, L.V.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501283/
https://www.ncbi.nlm.nih.gov/pubmed/22772054
http://dx.doi.org/10.1093/europace/eus188
_version_ 1782250173382000640
author Scharf, C.
Ng, G.A.
Wieczorek, M.
Deneke, T.
Furniss, S.S.
Murray, St.
Debruyne, Ph.
Hobson, N.
Berntsen, R.F.
Schneider, M.A.
Hauer, H.A.
Halimi, F.
Boveda, S.
Asbach, S.
Boesche, L.
Zimmermann, M.
Brigadeau, F.
Taieb, J.
Merkel, M.
Pfyffer, M.
Brunner-La Rocca, H.P.
Boersma, L.V.A.
author_facet Scharf, C.
Ng, G.A.
Wieczorek, M.
Deneke, T.
Furniss, S.S.
Murray, St.
Debruyne, Ph.
Hobson, N.
Berntsen, R.F.
Schneider, M.A.
Hauer, H.A.
Halimi, F.
Boveda, S.
Asbach, S.
Boesche, L.
Zimmermann, M.
Brigadeau, F.
Taieb, J.
Merkel, M.
Pfyffer, M.
Brunner-La Rocca, H.P.
Boersma, L.V.A.
author_sort Scharf, C.
collection PubMed
description AIMS: Duty-cycled radiofrequency ablation (RFA) has been used for atrial fibrillation (AF) for around 5 years, but large-scale data are scarce. The purpose of this survey was to report the outcome of the technique. METHODS AND RESULTS: A survey was conducted among 20 centres from seven European countries including 2748 patients (2128 with paroxysmal and 620 with persistent AF). In paroxysmal AF an overall success rate of 82% [median 80%, interquartile range (IQR) 74–90%], a first procedure success rate of 72% [median 74% (IQR 59–83%)], and a success of antiarrhythmic medication of 59% [median 60% (IQR 39–72%)] was reported. In persistent AF, success rates were significantly lower with 70% [median 74% (IQR 60–92%)]; P = 0.05) as well as the first procedure success rate of 58% [median 55% (IQR 47–81%)]; P = 0.001). The overall success rate was similar among higher and lower volume centres and were not dependent on the duration of experience with duty-cycled RFA (r = −0.08, P = 0.72). Complications were observed in 108 (3.9%) patients, including 31 (1.1%) with symptomatic transient ischaemic attack or stroke, which had the same incidence in paroxysmal and persistent AF (1.1 vs. 1.1%) and was unrelated to the case load (r = 0.24, P = 0.15), bridging anticoagulation to low molecular heparin, routine administration of heparin over the long sheath, whether a transoesophageal echocardiogram was performed in every patient or not and average procedure times. CONCLUSION: Duty-cycled RFA has a self-reported success and complication rate similar to conventional RFA. After technical modifications a prospective registry with controlled data monitoring should be conducted to assess outcome.
format Online
Article
Text
id pubmed-3501283
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-35012832012-11-19 European survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation Scharf, C. Ng, G.A. Wieczorek, M. Deneke, T. Furniss, S.S. Murray, St. Debruyne, Ph. Hobson, N. Berntsen, R.F. Schneider, M.A. Hauer, H.A. Halimi, F. Boveda, S. Asbach, S. Boesche, L. Zimmermann, M. Brigadeau, F. Taieb, J. Merkel, M. Pfyffer, M. Brunner-La Rocca, H.P. Boersma, L.V.A. Europace Clinical Research AIMS: Duty-cycled radiofrequency ablation (RFA) has been used for atrial fibrillation (AF) for around 5 years, but large-scale data are scarce. The purpose of this survey was to report the outcome of the technique. METHODS AND RESULTS: A survey was conducted among 20 centres from seven European countries including 2748 patients (2128 with paroxysmal and 620 with persistent AF). In paroxysmal AF an overall success rate of 82% [median 80%, interquartile range (IQR) 74–90%], a first procedure success rate of 72% [median 74% (IQR 59–83%)], and a success of antiarrhythmic medication of 59% [median 60% (IQR 39–72%)] was reported. In persistent AF, success rates were significantly lower with 70% [median 74% (IQR 60–92%)]; P = 0.05) as well as the first procedure success rate of 58% [median 55% (IQR 47–81%)]; P = 0.001). The overall success rate was similar among higher and lower volume centres and were not dependent on the duration of experience with duty-cycled RFA (r = −0.08, P = 0.72). Complications were observed in 108 (3.9%) patients, including 31 (1.1%) with symptomatic transient ischaemic attack or stroke, which had the same incidence in paroxysmal and persistent AF (1.1 vs. 1.1%) and was unrelated to the case load (r = 0.24, P = 0.15), bridging anticoagulation to low molecular heparin, routine administration of heparin over the long sheath, whether a transoesophageal echocardiogram was performed in every patient or not and average procedure times. CONCLUSION: Duty-cycled RFA has a self-reported success and complication rate similar to conventional RFA. After technical modifications a prospective registry with controlled data monitoring should be conducted to assess outcome. Oxford University Press 2012-12 2012-07-06 /pmc/articles/PMC3501283/ /pubmed/22772054 http://dx.doi.org/10.1093/europace/eus188 Text en Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2012. For permissions please email: journals.permissions@oup.com. http://creativecommons.org/licenses/by-nc/2.0/uk/ The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org.
spellingShingle Clinical Research
Scharf, C.
Ng, G.A.
Wieczorek, M.
Deneke, T.
Furniss, S.S.
Murray, St.
Debruyne, Ph.
Hobson, N.
Berntsen, R.F.
Schneider, M.A.
Hauer, H.A.
Halimi, F.
Boveda, S.
Asbach, S.
Boesche, L.
Zimmermann, M.
Brigadeau, F.
Taieb, J.
Merkel, M.
Pfyffer, M.
Brunner-La Rocca, H.P.
Boersma, L.V.A.
European survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation
title European survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation
title_full European survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation
title_fullStr European survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation
title_full_unstemmed European survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation
title_short European survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation
title_sort european survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501283/
https://www.ncbi.nlm.nih.gov/pubmed/22772054
http://dx.doi.org/10.1093/europace/eus188
work_keys_str_mv AT scharfc europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT ngga europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT wieczorekm europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT deneket europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT furnissss europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT murrayst europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT debruyneph europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT hobsonn europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT berntsenrf europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT schneiderma europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT hauerha europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT halimif europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT bovedas europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT asbachs europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT boeschel europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT zimmermannm europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT brigadeauf europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT taiebj europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT merkelm europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT pfyfferm europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT brunnerlaroccahp europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation
AT boersmalva europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation